Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
16
INTS Quote, Financials, Valuation and Earnings
Last price:
$0.33
Seasonality move
:
-27.87%
Day range:
$0.31 - $0.34
52-week range:
$0.26 - $5.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
17.92x
Volume:
2.5M
Avg. volume:
3.2M
1-year change:
-93.39%
Market cap:
$6M
Revenue:
--
EPS (TTM):
-$1.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INTS
Intensity Therapeutics
|
-- | -$0.18 | -- | -50% | $3.50 |
|
ARAY
Accuray
|
$124.5M | $0.02 | -7.31% | -50% | $5.17 |
|
CLRB
Cellectar Biosciences
|
-- | -$3.70 | -- | -31.48% | $4.00 |
|
IMRX
Immuneering
|
-- | -$0.42 | -- | -19.68% | $11.42 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INTS
Intensity Therapeutics
|
$0.33 | $3.50 | $6M | -- | $0.00 | 0% | -- |
|
ARAY
Accuray
|
$1.35 | $5.17 | $139.1M | -- | $0.00 | 0% | 0.29x |
|
CLRB
Cellectar Biosciences
|
$5.04 | $4.00 | $9.1M | -- | $0.00 | 0% | 137.94x |
|
IMRX
Immuneering
|
$3.96 | $11.42 | $142.5M | -- | $0.00 | 0% | 393.82x |
|
NBY
NovaBay Pharmaceuticals
|
$0.65 | $0.85 | $3.8M | -- | $0.00 | 0% | 0.16x |
|
TOVX
Theriva Biologics
|
$0.47 | $7.00 | $3.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INTS
Intensity Therapeutics
|
-- | 1.007 | -- | -- |
|
ARAY
Accuray
|
77.8% | 2.035 | 94.39% | 0.82x |
|
CLRB
Cellectar Biosciences
|
-- | 0.590 | -- | -- |
|
IMRX
Immuneering
|
-- | 6.440 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INTS
Intensity Therapeutics
|
-- | -$3.4M | -- | -- | -- | -$2M |
|
ARAY
Accuray
|
$31.6M | $1M | 0.31% | 1.47% | 1.81% | $15.6M |
|
CLRB
Cellectar Biosciences
|
-- | -$6.4M | -- | -- | -- | -$9.4M |
|
IMRX
Immuneering
|
-- | -$15.5M | -- | -- | -- | -$14.1M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Intensity Therapeutics vs. Competitors
-
Which has Higher Returns INTS or ARAY?
Accuray has a net margin of -- compared to Intensity Therapeutics's net margin of -1.15%. Intensity Therapeutics's return on equity of -- beat Accuray's return on equity of 1.47%.
Company Gross Margin Earnings Per Share Invested Capital INTSIntensity Therapeutics-- -$0.22 -- ARAYAccuray27.93% -$0.01 $223.4M -
What do Analysts Say About INTS or ARAY?
Intensity Therapeutics has a consensus price target of $3.50, signalling upside risk potential of 975.93%. On the other hand Accuray has an analysts' consensus of $5.17 which suggests that it could grow by 282.72%. Given that Intensity Therapeutics has higher upside potential than Accuray, analysts believe Intensity Therapeutics is more attractive than Accuray.
Company Buy Ratings Hold Ratings Sell Ratings INTSIntensity Therapeutics1 2 0 ARAYAccuray2 0 0 -
Is INTS or ARAY More Risky?
Intensity Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Accuray has a beta of 1.260, suggesting its more volatile than the S&P 500 by 25.978%.
-
Which is a Better Dividend Stock INTS or ARAY?
Intensity Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intensity Therapeutics pays -- of its earnings as a dividend. Accuray pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INTS or ARAY?
Intensity Therapeutics quarterly revenues are --, which are smaller than Accuray quarterly revenues of $113.2M. Intensity Therapeutics's net income of -$3.3M is lower than Accuray's net income of -$1.3M. Notably, Intensity Therapeutics's price-to-earnings ratio is -- while Accuray's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intensity Therapeutics is -- versus 0.29x for Accuray. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INTSIntensity Therapeutics-- -- -- -$3.3M ARAYAccuray0.29x -- $113.2M -$1.3M
-
Which has Higher Returns INTS or CLRB?
Cellectar Biosciences has a net margin of -- compared to Intensity Therapeutics's net margin of --. Intensity Therapeutics's return on equity of -- beat Cellectar Biosciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INTSIntensity Therapeutics-- -$0.22 -- CLRBCellectar Biosciences-- -$4.20 -- -
What do Analysts Say About INTS or CLRB?
Intensity Therapeutics has a consensus price target of $3.50, signalling upside risk potential of 975.93%. On the other hand Cellectar Biosciences has an analysts' consensus of $4.00 which suggests that it could grow by 2280.96%. Given that Cellectar Biosciences has higher upside potential than Intensity Therapeutics, analysts believe Cellectar Biosciences is more attractive than Intensity Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings INTSIntensity Therapeutics1 2 0 CLRBCellectar Biosciences2 2 0 -
Is INTS or CLRB More Risky?
Intensity Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cellectar Biosciences has a beta of 0.507, suggesting its less volatile than the S&P 500 by 49.315%.
-
Which is a Better Dividend Stock INTS or CLRB?
Intensity Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intensity Therapeutics pays -- of its earnings as a dividend. Cellectar Biosciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INTS or CLRB?
Intensity Therapeutics quarterly revenues are --, which are smaller than Cellectar Biosciences quarterly revenues of --. Intensity Therapeutics's net income of -$3.3M is higher than Cellectar Biosciences's net income of -$6.6M. Notably, Intensity Therapeutics's price-to-earnings ratio is -- while Cellectar Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intensity Therapeutics is -- versus 137.94x for Cellectar Biosciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INTSIntensity Therapeutics-- -- -- -$3.3M CLRBCellectar Biosciences137.94x -- -- -$6.6M
-
Which has Higher Returns INTS or IMRX?
Immuneering has a net margin of -- compared to Intensity Therapeutics's net margin of --. Intensity Therapeutics's return on equity of -- beat Immuneering's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INTSIntensity Therapeutics-- -$0.22 -- IMRXImmuneering-- -$0.42 -- -
What do Analysts Say About INTS or IMRX?
Intensity Therapeutics has a consensus price target of $3.50, signalling upside risk potential of 975.93%. On the other hand Immuneering has an analysts' consensus of $11.42 which suggests that it could grow by 188.3%. Given that Intensity Therapeutics has higher upside potential than Immuneering, analysts believe Intensity Therapeutics is more attractive than Immuneering.
Company Buy Ratings Hold Ratings Sell Ratings INTSIntensity Therapeutics1 2 0 IMRXImmuneering3 1 0 -
Is INTS or IMRX More Risky?
Intensity Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immuneering has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock INTS or IMRX?
Intensity Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuneering offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intensity Therapeutics pays -- of its earnings as a dividend. Immuneering pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INTS or IMRX?
Intensity Therapeutics quarterly revenues are --, which are smaller than Immuneering quarterly revenues of --. Intensity Therapeutics's net income of -$3.3M is higher than Immuneering's net income of -$15M. Notably, Intensity Therapeutics's price-to-earnings ratio is -- while Immuneering's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intensity Therapeutics is -- versus 393.82x for Immuneering. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INTSIntensity Therapeutics-- -- -- -$3.3M IMRXImmuneering393.82x -- -- -$15M
-
Which has Higher Returns INTS or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Intensity Therapeutics's net margin of -49.65%. Intensity Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital INTSIntensity Therapeutics-- -$0.22 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About INTS or NBY?
Intensity Therapeutics has a consensus price target of $3.50, signalling upside risk potential of 975.93%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Intensity Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Intensity Therapeutics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings INTSIntensity Therapeutics1 2 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is INTS or NBY More Risky?
Intensity Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock INTS or NBY?
Intensity Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intensity Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INTS or NBY?
Intensity Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Intensity Therapeutics's net income of -$3.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Intensity Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intensity Therapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INTSIntensity Therapeutics-- -- -- -$3.3M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns INTS or TOVX?
Theriva Biologics has a net margin of -- compared to Intensity Therapeutics's net margin of --. Intensity Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INTSIntensity Therapeutics-- -$0.22 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About INTS or TOVX?
Intensity Therapeutics has a consensus price target of $3.50, signalling upside risk potential of 975.93%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Intensity Therapeutics, analysts believe Theriva Biologics is more attractive than Intensity Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings INTSIntensity Therapeutics1 2 0 TOVXTheriva Biologics1 1 0 -
Is INTS or TOVX More Risky?
Intensity Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock INTS or TOVX?
Intensity Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intensity Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INTS or TOVX?
Intensity Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Intensity Therapeutics's net income of -$3.3M is higher than Theriva Biologics's net income of -$4.3M. Notably, Intensity Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intensity Therapeutics is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INTSIntensity Therapeutics-- -- -- -$3.3M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
